InflaRx Investor Relations Material

InflaRx N.V. is a clinical-stage biopharmaceutical company engaged in the discovery and development of drugs that inhibit the activation of the complement system, particularly targeting the C5a component, a potent inflammatory mediator. This focus addresses various autoimmune and other inflammatory diseases. The company's leading product candidate, vilobelimab, is a first-in-class anti-C5a monoclonal antibody with multiple clinical applications, including for diseases like hidradenitis suppurativa and cutaneous squamous cell carcinoma. The company is headquartered in Jena, Germany, and its shares are listed on the NASDAQ.